1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > BUCCAL DRUG DELIVERY SYSTEMS: OPPORTUNITIES AND CHALLENGES IN BUCCAL, SUBLINGUAL FILMS, TABLETS & SPRAYS - Detailed analysis on Technologies and Pipeline Development

Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and it is relatively permeable. The buccal mucosa offers several advantages for controlled drug delivery for extended periods of time. The mucosa is well supplied with both vascular and lymphatic drainage and first-pass metabolism in the liver and pre-systemic elimination in the gastrointestinal tract are avoided. The area is well suited for a retentive device and appears to be acceptable to the patient. With the right dosage form design and formulation, the permeability and the local environment of the mucosa can be controlled and manipulated in order to accommodate drug permeation. Buccal drug delivery is a promising area for continued research with the aim of systemic delivery of orally inefficient drugs as well as a feasible and attractive alternative for non-invasive delivery of potent peptide and protein drug molecules. In 2014, sales of Suboxone sublingual film totalled approximately $1.3 billion in the U.S. while the total market grew to more than $1.7 billion, driven by a 11 percent increase in prescriptions. In 2014, Bunavail buccal film has received US approval which has similar bioavailability of suboxone with half of the dose of buprenorphine.

Other than drugs used for local actions (antifungal, antiviral), generally controlled substances like buprenorphine, naloxone and fentanyl are preferred to release the drug through buccal formulations. However, testosterone (striant) to treat low testosterone levels in men also approved through use of buccal system of delivery. In the US, drugs such as Isosorbide dinitarte, ergoloid delivered sublingually have been discontinued and nitroglycerin has been replaced with sublingual metered spray. Ergomar (ergotamine tartarate) marketed by Rosedale therapeutics is the only sublingual tablets available in the US market, priced $15 per pill.

Subsys (fentanyl) developed by Insys therapeutics was the recent sublingual spray approved in the US for the treatment of breakthrough cancer pain.

Global pharma companies such as Biodelivery Sciences, Bioalliance pharma (Onexo), Meda pharma, Orexo, Generex, Teijin are actively involved in developing oral mucoadhesive buccal delivery systems while sublingual technology have been used by Teva, Sun pharma, Grunenthal, Neurax, Angelini, Sandoz, Ethypharm, Arrow generics, Purdue and Actavis pharma. Sublingual spray technology have been employed by the companies such as Insys therapeutics, Perrigo, Mist pharm, Regency, Novadel, Generex, GW Pharma and Pohl Boskamp in developing potential drugs for the patients.

Ease of administration and better compliance offered by delivering through buccal route offers advantages for patients and physicians over other Invasive route and oral ingestion will drive the market further in positive directions going forward. Novel buccal delivery such as soluble thin films, mucoadhesive films and rapidmist spray offers newer route of delivery for the generics that has lesser patients compliances.

This report will provide detailed analysis on buccal delivery systems in broader pharma market in finding companies and technologies and complexities involved in developing this unique high potential delivery system

Table Of Contents

BUCCAL DRUG DELIVERY SYSTEMS: OPPORTUNITIES AND CHALLENGES IN BUCCAL, SUBLINGUAL FILMS, TABLETS and SPRAYS - Detailed analysis on Technologies and Pipeline Development
1. Introduction
2. Types of dosage forms
3. Transmucosal Delivery Systems: The Mouth
4. Potential Benefits of Buccal Films
5. Limitations and Challenges of Buccal delivery system
6. Buccal Films
- Formulation aspects
- Ideal Characteristic of drugs/excipients for developing Buccal delivery formulations
- Manufacturing Methods
o Solvent casting method
o Hot-melt extrusion
o Semisolid casting
o Solid dispersion
o Rolling
- Physico-Chemical Evaluation of Buccal Films
- Marketed Buccal Films
- Technologies used in Buccal/Sublingual films
o BEMA
o PharmaFilm

?
7. Buccal Tablets
- Lauriad mucoadhesive technology (Onexo)
- OraVescent Technology (Cima Labs)

8. Sublingual films/Tablets
Buccal/ sublingual formulations approved in the US including generics
Buccal/ sublingual formulations discontinued in the US
Buccal/ sublingual formulations underdevelopment worldwide
Buccal /sublingual formulations approved in Europe
9. Other technologies used in buccal delivery systems
- ArisGen Pharma (ArisCrown technology)
- Mystic Pharma (VersiDoser powder technology)
- Uluru (OraDisc Technology)
- Tesa labtec (PerioPatch) - buccal patch
- Intellidrug (Intraoral drug delivery device)
- Generex Pharma (RapidMist Technology)
- Insys therapeutics (sublingual spray)

10. Oral Thin fast Dissolving Films (OTF) -Ideal Characteristics, Classification and Evaluation
- Auxillium Pharma (PharmForm Tech)
- LTS Lohmann OTF
- IntelGenx OTF
- Tapemark Solustrip technology
- Applied Pharma Research/Tesa Labtec - RapidFilm Technology
- Tesa Labtec Pharma -Mucofilm
- Cynapsus Pharma - Sublingual thin film
- Seoul Pharma -SmartFilm
- Other patented approaches
o XGel film
o Soluleaves
o Wafertab
o Foamburst
o Micap
Companies Covered
- Actavis
- Angelini
- Applied Pharma Research
- Ardana Biosciences
- Auxillium Pharma
- Barr
- Biodelivery Sciences
- Blue fish
- Cynapsus Pharma
- Ethypharm
- Galena
- Galenica
- Generex
- Grunenthal
- Indivior
- Insys
- Insys Therapeutics
- IntelGenx
- Intellidrug
- LTS Lohmann
- Meda Pharma
- MedaPharm
- Mist Pharma
- Mystic Pharma
- Neuraxpharm
- Novadel
- Novel Labs
- Nycomed
- Onexo
- Oriform
- Purdue
- Rosedale Therapeutics
- Roxane
- Sandoz
- Sanofi
- Snoreeze
- Tapemark
- Tesa Labtec Pharma
- Teva

Charts
Chart 1: Drug in Mucoadhesive Thin Film Matrix
Chart 2: Ideal properties of Mucoadhesive polymers
Chart 3: Buccal and Oral Delivery of Peptides through Ariscrown
Chart 4: Oral Peptide Delivery Pipeline from ArisGen Pharma
Chart 5: VersiDoser from Mystic Pharma
Chart 6: Clinical profile of Oral-Lyn in Comparison with Humulin (LLY)

Tables
Table 1: List of Approved formulations in mucoadhesive systems worldwide
Table 2: List of Marketed Mucoadhesive Drugs Developed Outside the US
Table 3: List of USFDA approved Buccal formulations
Table 4: List of Sublingual Delivery Formulations Approved by the USFDA
Table 5: List of Discontinued Buccal And Sublingual Formulations from the US market
Table 6: List of Sublingual Formulations Approved in Europe
Table 7: List of Buccal Formulations Approved in Europe
Table 8: List of Mucoadhesive delivery drugs under clinical development
Table 9: Classification of Oral Fast Dissolving Technologies
Table 10: Approved Formulations using Oral Thin Film Technologies
Table 11: Physico-chemical Properties of Mucoadhesive Wafers (Oral Thin Films)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.